Page last updated: 2024-08-17

carbostyril and Granulocytic Leukemia, Chronic

carbostyril has been researched along with Granulocytic Leukemia, Chronic in 9 studies

Research

Studies (9)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	5 (55.56)	29.6817
2010's	3 (33.33)	24.3611
2020's	1 (11.11)	2.80

Authors

Authors	Studies
Eşkazan, AE; Özgür Yurttaş, N	1
Fukuda, T; Kasama, T; Miura, O; Suwa, S; Uchida, E; Watanabe, K; Yoshimoto, R	1
Engels, JW; Gambari, R; Saab, AM; Wicke, L	1
Blaskovich, MA; Burton, M; Cubitt, C; Duong, VH; Lancet, JE; Sebti, S; Stuart, RK; Sullivan, DM; Winton, EF; Wright, JJ; Zhang, S	1
Albitar, M; Cortes, J; Garcia-Manero, G; Giles, F; Kantarjian, H; Koller, C; Kurzrock, R; O'Brien, S; Rackoff, W; Talpaz, M; Thibault, A; Thomas, D	1
Tauchi, T	1
Hayashi, Y	1
Cortes, J; Ebarb, T; Faderl, S; Garcia-Manero, G; Giles, F; Jones, D; Kantarjian, H; O'Brien, S; Quintás-Cardama, A; Thomas, D	1
Ange, D; Belly, RT; Bol, K; Buddharaju, L; End, DW; Gojo, I; Highsmith, WE; Hohl, RJ; Horak, I; Karp, JE; Kaufmann, SH; Kottke, TJ; Lancet, JE; Liesveld, J; Rosenblatt, J; Rybak, ME; Thibault, A; Tidwell, ML; Wright, JJ	1

Reviews

2 review(s) available for carbostyril and Granulocytic Leukemia, Chronic

Article	Year
Novel therapeutic approaches in chronic myeloid leukemia. Leukemia research, 2020, Volume: 91 Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Resistance, Neoplasm; Everolimus; Fusion Proteins, bcr-abl; Gene Expression; Histone Deacetylase Inhibitors; Homoharringtonine; Humans; Immunotherapy; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Niacinamide; Piperidines; Polyethylene Glycols; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinolones; Recombinant Proteins	2020
[Molecular pathogenesis of chronic myeloid leukemia and tyrosine kinase inhibitor]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2004, Volume: 45, Issue:1 Topics: Animals; Benzamides; Chromosome Aberrations; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Piperidines; Pyridines; Pyrimidines; Quinolones; Randomized Controlled Trials as Topic; Thionucleotides	2004

Article

Year

Novel therapeutic approaches in chronic myeloid leukemia.

Leukemia research, 2020, Volume: 91

Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Resistance, Neoplasm; Everolimus; Fusion Proteins, bcr-abl; Gene Expression; Histone Deacetylase Inhibitors; Homoharringtonine; Humans; Immunotherapy; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Niacinamide; Piperidines; Polyethylene Glycols; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinolones; Recombinant Proteins

2020

[Molecular pathogenesis of chronic myeloid leukemia and tyrosine kinase inhibitor].

[Rinsho ketsueki] The Japanese journal of clinical hematology, 2004, Volume: 45, Issue:1

Topics: Animals; Benzamides; Chromosome Aberrations; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Piperidines; Pyridines; Pyrimidines; Quinolones; Randomized Controlled Trials as Topic; Thionucleotides

2004

Trials

4 trial(s) available for carbostyril and Granulocytic Leukemia, Chronic

Article	Year
A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Mar-01, Volume: 17, Issue:5 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chymotrypsin; Farnesyltranstransferase; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Male; Maximum Tolerated Dose; Middle Aged; NF-kappa B; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Inhibitors; Pyrazines; Quinolones	2011
Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood, 2003, Mar-01, Volume: 101, Issue:5 Topics: Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Agents; Blast Crisis; Drug Administration Schedule; Drug Eruptions; Endothelial Growth Factors; Enzyme Inhibitors; Farnesyltranstransferase; Fatigue; Female; Fibroblast Growth Factor 2; Hepatocyte Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Lymphokines; Male; Middle Aged; Multiple Myeloma; Nausea; Neoplasm Proteins; Primary Myelofibrosis; Quinolones; Salvage Therapy; Treatment Outcome; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors	2003
Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure. Cancer, 2007, Nov-01, Volume: 110, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Maximum Tolerated Dose; Middle Aged; Piperazines; Pyrimidines; Quinolones	2007
Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood, 2001, Jun-01, Volume: 97, Issue:11 Topics: Adult; Aged; Alkyl and Aryl Transferases; Bone Marrow; Cohort Studies; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Farnesyltranstransferase; Female; Genes, ras; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Mutation; Phosphorylation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Prenylation; Quinolones; Recurrence; Remission Induction; Treatment Outcome	2001

Other Studies

3 other study(ies) available for carbostyril and Granulocytic Leukemia, Chronic

Article	Year
TOPK is regulated by PP2A and BCR/ABL in leukemia and enhances cell proliferation. International journal of oncology, 2019, Volume: 54, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Blast Crisis; Cell Line, Tumor; Cell Proliferation; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; HLA-A24 Antigen; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Phosphorylation; Protein Phosphatase 2; Quinolones; Thiophenes; Young Adult	2019
Synthesis and antiproliferative activity of quinolone nucleosides against the human myelogenous leukemia k-562 cell line. Archiv der Pharmazie, 2013, Volume: 346, Issue:10 Topics: Antineoplastic Agents; Cell Proliferation; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nucleosides; Quinolones; Structure-Activity Relationship	2013
[Prognostic molecular marker and molecular targeted-therapy in pediatric malignancies]. Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Biomarkers, Tumor; Child; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Hematologic Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Loss of Heterozygosity; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Quinolones; Rituximab; Tretinoin	2007